SCHEMBL5203205

SCHEMBL5203205

CCOc1ccc2cc(C(=O)O)c(Nc3cccc(Cl)c3)nc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 1/20 0.53
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
HPGD P15428 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
GFER P55789 1/20 0.49
AKR1C3 P42330 1/20 0.48
AKR1C2 P52895 1/20 0.48
CSNK2A1 P68400 8/20 0.47
CSNK2A2 P19784 6/20 0.47
CSNK2B P67870 6/20 0.47
FBP1 P09467 1/20 0.46
EGFR P00533 2/20 0.45
SYK P43405 1/20 0.44
ALOX15 P16050 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5207437 0.88 MEN1 (0.64) FADS1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL5204584 0.84 CSNK2A1 (0.56) MEN1KMT2AHPGDSMN1; SMN2LMNA
SCHEMBL5204744 0.84 CSNK2A1 (0.49) MEN1KMT2AHPGDSMN1; SMN2LMNA
SCHEMBL5207731 0.82 ALDH1A1 (0.52) FADS1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL4503390 0.81 PIM1 (0.55) MEN1KMT2ACSNK2A1CSNK2A2CSNK2B
SCHEMBL5205531 0.81 MAPT (0.53) MEN1KMT2AHPGDSMN1; SMN2AKR1C3
SCHEMBL5202883 0.80 CSNK2A1 (0.49) MEN1KMT2AHPGDSMN1; SMN2LMNA
SCHEMBL5205074 0.80 MEN1 (0.64) FADS1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL5202960 0.80 CSNK2A1 (0.61) FADS1MEN1KMT2ASMN1; SMN2CSNK2A1
SCHEMBL5204702 0.79 CSNK2A1 (0.48) FADS1MEN1KMT2AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1372654-A4 QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES SMITHKLINE BEECHAM CORP (US) 2007-10-03 EP disclosed
US-7087758-B2 Quinoline inhibitors of hyaki and hyak3 kinases SMITHKLINE BEECHAM CORPORATION (US) 2006-08-08 US disclosed
US-20050043352-A1 Quinoline inhibitors of hyaki and hyak3 kinases SMITHKLINE BEECHAM CORPORATION 2005-02-24 US disclosed
EP-1372654-A2 QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES SmithKline Beecham Corporation (US) 2004-01-02 EP disclosed
WO-2002081728-A2 QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES SMITHKLINE BEECHAM CORPORATION (US) 2002-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043352-A1 Quinoline inhibitors of hyaki and hyak3 kinases HIPK3, HIPK1, HYPK FADS1 2877/4885MEN1 2633/4885KMT2A 1719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.